Study of LP002 in Combination With Chemotherapy for Patients With Extensive Stage Small Cell Lung Cancer

NCT04740021 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

46

Enrollment

INDUSTRY

Sponsor class

Conditions

Small-cell Lung Cancer

Interventions

DRUG: LP002
DRUG: Carboplatin
DRUG: Etoposide

Sponsor

Taizhou HoudeAoke Biomedical Co., Ltd.